Browse Arkansas Code titles and sections
23-79-1301. Findings.
Arkansas Code — all titles (historical 2020) · legal_authorities
23-79-1301. Findings.
The General Assembly finds that:
(1) Prostate cancer is the second leading cause of cancer in men;
(2) In Arkansas, more men die from prostate cancer than women die of breast cancer, the tenth-highest death rate in the nation;
(3) Even though the death rate for prostate cancer has decreased in Arkansas, there has been a fifty-five percent (55%) increase in premature death before sixty-five (65) years of age;
(4) Arkansas's African-American men are fifty-five percent (55%) more likely to develop prostate cancer and one hundred seventy-six percent (176%) more likely to die from prostate cancer than Arkansas's Caucasian men;
(5) The Arkansas Central Cancer Registry data indicates that there has been a steady increase in the number of new cases of prostate cancer and a steady decrease in deaths from prostate cancer in Arkansas since 1999, indicating that there have been improvements in discovering prostate cancer before symptoms appear;
(6) Studies have found that men between fifty (50) years of age and sixty (60) years of age who were diagnosed with prostate cancer were sixty percent (60%) more likely to suffer premature death than those men who were diagnosed at an earlier age;
(7) Identifying the characteristics of high-risk men and fostering early diagnosis and appropriate treatment could:
(A) Prevent premature deaths;
(B) Decrease:
(i) Adverse effects and death from prostate cancer, particularly in the underserved populations;
(ii) Health disparities; and
(iii) Prostate cancer treatment costs through diagnosis at an earlier stage; and
(C) Improve and extend quality of life; and
(8) The cost of treatment per man for:
(A) Early-stage prostate cancer is fifty-eight thousand dollars ($58,000); and
(B) Late-stage prosta
Source: Arkansas Code — historical release 78 (November 6, 2020) · 23-79-1301
Stored review status: Historical 2020-11-06 source release; later amendments not reconciled; machine-extracted, not independently legally reviewed; source heading status: text_in_historical_source. A text match is a research starting point; applicability is not established.
Issuing source page ↗
Authority boundary: historical statutory source snapshot not current law.
Open the recorded source website ↗
Record provenance
Stable record: arkansas_code:legal_authorities:23-79-1301
Source file: gov.ar.code.title.23.odt
Pages: Not recorded – Not recorded
Passage SHA-256: a0064832080385c0c324ea627b9e9c0b58dcb8ef067f45bb0238d4d25ee9cc46
Source location: content.xml paragraph 47837
Stored source content
23-79-1301. Findings.
The General Assembly finds that:
(1) Prostate cancer is the second leading cause of cancer in men;
(2) In Arkansas, more men die from prostate cancer than women die of breast cancer, the tenth-highest death rate in the nation;
(3) Even though the death rate for prostate cancer has decreased in Arkansas, there has been a fifty-five percent (55%) increase in premature death before sixty-five (65) years of age;
(4) Arkansas's African-American men are fifty-five percent (55%) more likely to develop prostate cancer and one hundred seventy-six percent (176%) more likely to die from prostate cancer than Arkansas's Caucasian men;
(5) The Arkansas Central Cancer Registry data indicates that there has been a steady increase in the number of new cases of prostate cancer and a steady decrease in deaths from prostate cancer in Arkansas since 1999, indicating that there have been improvements in discovering prostate cancer before symptoms appear;
(6) Studies have found that men between fifty (50) years of age and sixty (60) years of age who were diagnosed with prostate cancer were sixty percent (60%) more likely to suffer premature death than those men who were diagnosed at an earlier age;
(7) Identifying the characteristics of high-risk men and fostering early diagnosis and appropriate treatment could:
(A) Prevent premature deaths;
(B) Decrease:
(i) Adverse effects and death from prostate cancer, particularly in the underserved populations;
(ii) Health disparities; and
(iii) Prostate cancer treatment costs through diagnosis at an earlier stage; and
(C) Improve and extend quality of life; and
(8) The cost of treatment per man for:
(A) Early-stage prostate cancer is fifty-eight thousand dollars ($58,000); and
(B) Late-stage prostate cancer is more than ninety-three thousand dollars ($93,000).
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
No explicit source connection was found. This does not mean there are no relevant authorities.